How to Apply for TGA ARTG Listed Medicine Status: Taiwan Exporter Walkthrough

The Australian Register of Therapeutic Goods (ARTG) is the mandatory gateway for any therapeutic product sold in Australia, administered by the Therapeutic Goods Administration under the Therapeutic Goods Act 1989. Products are classified into two primary pathways: AUST L (listed medicines) for lower-risk complementary medicines such as vitamins, minerals, herbal supplements, and traditional Chinese medicine formulations, and AUST R (registered medicines) for higher-risk products making specific therapeutic claims. For most Taiwan supplement and health product exporters, the AUST L pathway is the relevant entry point because it covers approximately 85 percent of the complementary medicine market in Australia, which was valued at AUD 5.69 billion in 2025.

The distinction between listed and registered medicines has direct commercial implications. AUST L products can only make indications from the TGA's pre-approved list of permitted indications, which includes over 1,200 health claims ranging from general wellness to specific physiological effects. You cannot claim that a listed medicine treats, cures, or prevents a disease. AUST R products can make stronger therapeutic claims but require clinical trial data and a review process that takes 12 to 18 months and costs AUD 50,000 to AUD 200,000 in fees alone. For Taiwan brands entering Australia for the first time, starting with AUST L products is the pragmatic choice because the application can be completed in 60 to 90 working days at a fraction of the cost.

Every product listed on the ARTG receives a unique AUST L number (for example, AUST L 123456) that must appear on the product label. Australian retailers, pharmacies, and online marketplaces require this number before accepting any therapeutic product for sale. Chemist Warehouse, Priceline Pharmacy, and Amazon Australia all verify ARTG listing status before onboarding health supplement suppliers. Without a valid AUST L number, your product cannot legally be sold, advertised, or even sampled in Australia, and penalties for unlisted therapeutic goods can reach AUD 1.11 million per offense under the 2023 penalty framework.

Taiwan brands must also understand that the TGA conducts post-market surveillance of listed medicines through a random testing program called the Listed Medicines Compliance Review. Each year, the TGA tests approximately 200 to 300 listed products for ingredient identity, potency, contamination, and label accuracy. Products that fail compliance review face mandatory recall, suspension from the ARTG, and public notification on the TGA website. This means your manufacturing quality and label accuracy must meet Australian standards not just at the time of application but continuously. Establishing a robust quality management system before applying is essential to long-term success in the Australian market.

Before submitting an ARTG application, two prerequisites must be in place: GMP clearance for your manufacturing facility and an Australian sponsor entity. GMP clearance confirms that your factory meets the Therapeutic Goods (Manufacturing Principles) Determination, which aligns with the PIC/S Guide to Good Manufacturing Practice. Taiwan manufacturers can apply for GMP clearance through the TGA by submitting a Site Master File, quality manual, batch records, and stability data. The TGA charges AUD 34,300 for an overseas GMP audit (2025 fee schedule) and the audit typically occurs within 6 to 9 months of application. If your factory already holds PIC/S GMP certification from Taiwan's TFDA or another PIC/S member authority, you can apply for mutual recognition, which reduces the timeline to 3 to 4 months.

The Australian sponsor is the legal entity responsible for the product on Australian soil. The sponsor must be a company registered with the Australian Securities and Investments Commission (ASIC) with an Australian business address. Taiwan companies cannot directly sponsor their own products unless they establish an Australian subsidiary or branch office. The most common approach for Taiwan brands is to appoint an Australian regulatory affairs company or distribution partner as the sponsor. Sponsor fees typically range from AUD 3,000 to AUD 8,000 per product per year for a regulatory affairs firm, or are bundled into the distribution margin (15 to 25 percent of wholesale) when using a full-service distributor.

Your sponsor bears legal responsibility for the product, which means they will perform their own due diligence on your manufacturing quality, ingredient sourcing, and label claims. A competent sponsor will request your certificate of analysis for every active ingredient, stability study reports (minimum 12 months accelerated and 24 months real-time for the Australian climate zone), heavy metal and microbiological test results, and evidence supporting every indication you plan to include on the label. Prepare these documents in English and in formats that comply with the TGA's Evidence Guidelines for listed medicines before approaching potential sponsors.

Taiwan brands should budget AUD 15,000 to AUD 35,000 for the complete pre-application phase, including GMP clearance fees, sponsor engagement, regulatory consulting, and documentation preparation. This investment is a one-time cost per manufacturing facility (GMP clearance) plus an annual per-product cost (sponsor fees and ARTG annual charges of AUD 1,340 per listed product in 2025). Compared to the US FDA pathway for dietary supplements, which has no pre-market approval requirement, the Australian TGA pathway is more rigorous but provides a significant competitive advantage: your AUST L number serves as a trust signal that Australian consumers and retailers actively look for when choosing supplements.

ARTG applications for listed medicines are submitted through the TGA's electronic Business Services (eBusiness) portal at ebs.tga.gov.au. The process begins with creating a TGA eBusiness account for your Australian sponsor, which requires an AUSkey or myGovID business credential. Once logged in, select "Application for New Listed Medicine" and complete the online form in four sections: product details, composition, indications, and manufacturing information. The application fee for a new AUST L listing is AUD 1,660 (2025 schedule), payable by credit card or electronic funds transfer at the time of submission.

The composition section requires you to declare every active and excipient ingredient using the TGA's standardized ingredient names from the Electronic Listing Facility (ELF) ingredient database. Each active ingredient must specify the exact quantity per dosage unit, the plant part used (for herbal ingredients), the extraction ratio and solvent (for extracts), and the equivalent dry weight. Common rejection reasons include using proprietary ingredient names not found in the ELF database, failing to specify extraction ratios for standardized extracts, and declaring ingredient quantities that differ from the certificate of analysis. Cross-reference your formulation against the ELF database before submission to prevent automatic rejection.

The indications section allows you to select health claims from the TGA's list of permitted indications. You may select multiple indications but each must be supportable by the evidence held by the sponsor. The TGA does not require you to submit evidence at the time of application for AUST L products, but the sponsor must hold the evidence on file and produce it within 20 business days if requested during a compliance review. Acceptable evidence types include human clinical trials published in peer-reviewed journals, systematic reviews, monographs from recognized compendia (British Pharmacopoeia, European Pharmacopoeia, WHO monographs), and traditional use evidence for products marketed for at least 75 years. Building your evidence dossier before application ensures you can defend every claim on your label.

After submission, the TGA aims to process AUST L applications within 40 to 60 working days. If the application meets all requirements, the product is listed on the ARTG and assigned an AUST L number. The TGA publishes the listing on the public ARTG database (tga.gov.au/artg), making it searchable by retailers, consumers, and compliance officers. If deficiencies are found, the TGA issues a Request for Information (RFI) with a 20-working-day response deadline. Failing to respond to an RFI within the deadline results in application lapse, requiring a new application and new fee. Taiwan brands should designate a responsive regulatory contact in Australia who can address RFIs within the timeframe.

The TGA rejects approximately 15 to 20 percent of new AUST L applications on first submission, primarily due to compositional errors and non-compliant ingredient declarations. The most frequent rejection reason is the use of ingredients not listed in the TGA's Permissible Ingredients Determination. Taiwan herbal formulations often contain traditional Chinese medicine ingredients that are not yet on the permitted list, requiring a separate application to the TGA's Complementary Medicines Evaluation Committee to add the ingredient. This process takes 6 to 12 months and costs AUD 12,800 per ingredient application. Check every ingredient against the current Permissible Ingredients list before developing your Australian formulation.

Label compliance errors account for approximately 25 percent of post-listing compliance failures. The TGA requires specific label elements including the AUST L number, sponsor name and address, complete ingredient list with quantities, indications exactly as approved, directions for use, storage conditions, batch number, and expiry date. Labels must comply with the Therapeutic Goods Order No. 69 (TGO 69) for general requirements and TGO 92 for specific labeling of medicines. Font size minimums apply: the AUST L number and sponsor details must be at least 1.5mm in height. Taiwan brands should engage an Australian regulatory labeling specialist (AUD 1,500 to AUD 3,000 per SKU) to review labels before printing.

Stability data deficiencies are a growing area of TGA scrutiny. The TGA expects stability studies conducted in accordance with ICH guidelines Q1A(R2), with testing at Zone II (25 degrees Celsius, 60 percent relative humidity) or Zone IVb (30 degrees Celsius, 75 percent relative humidity) for products sold in tropical regions of Australia. A minimum of 12 months real-time stability data is required at the time of listing, with ongoing stability testing throughout the product's shelf life. Products claiming a 3-year shelf life must have 36 months of real-time data to support the claim. Start stability studies at least 18 months before your planned Australia launch to have sufficient data.

Manufacturing compliance issues arise when the declared manufacturing site does not hold current TGA GMP clearance or when the actual manufacturing process differs from what was described in the application. The TGA cross-references your application against GMP clearance records and can request batch manufacturing records for verification. If your product is manufactured at multiple sites (for example, bulk manufacturing in Taiwan and packaging in Australia), each site must hold appropriate GMP clearance. Ensure your sponsor has current copies of all GMP certificates and that your application accurately describes the complete manufacturing chain from raw material to finished product.

Maintaining an ARTG listing requires ongoing compliance activities that Taiwan brands must plan for from day one. The annual charge for each AUST L listing is AUD 1,340 (2025 schedule), payable each October. Failure to pay the annual charge within 28 days of the due date results in automatic cancellation of the listing, which means your product becomes illegal to sell in Australia. Set up automated payment reminders and ensure your sponsor has a clear process for annual renewal. If a listing is cancelled for non-payment, you must submit a completely new application with a new fee to reinstate it.

The TGA requires sponsors to report adverse events associated with their products within 15 calendar days for serious adverse events and within 90 days for non-serious events. Your Australian sponsor must maintain an adverse event reporting system that captures consumer complaints, pharmacist reports, and any information about product-related health issues. Taiwan brands should establish a direct communication channel with their sponsor for adverse event notifications and include a consumer contact line (Australian phone number) on all product labels. The TGA publishes a database of adverse event reports that competitors, retailers, and media can access, making prompt and transparent reporting a brand protection priority.

Product variations, such as changes to ingredients, quantities, indications, labels, or manufacturing sites, require formal notification to the TGA before implementation. Minor variations (such as adding an alternative supplier for an excipient) can be self-assessed by the sponsor. Major variations (such as changing an active ingredient quantity or adding a new indication) require a new application or a formal variation request to the TGA, which carries a fee of AUD 830 to AUD 1,660 depending on the type of change. Plan your Australian product formulation carefully to minimize the need for variations in the first 2 to 3 years of market entry.

The TGA's post-market surveillance program randomly selects listed medicines for laboratory testing. If your product is selected, the TGA will purchase samples from retail outlets and test them for identity, assay (active ingredient content), dissolution, microbiological quality, and heavy metals. Results that fall outside pharmacopoeial specifications trigger an investigation that can lead to product recall, ARTG suspension, and referral for regulatory action. Taiwan brands should implement a retain sample program (keeping samples from every batch shipped to Australia) and conduct independent Australian laboratory testing annually as a preventive measure. Budget AUD 3,000 to AUD 8,000 per year for independent quality testing through a NATA-accredited Australian laboratory.